REFERENCES

1. Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, et al. Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007. Neuro Oncol 2017;19:1553-64.

2. Khanna V, Achey RL, Ostrom QT, Block-Beach H, Kruchko C, et al. Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. J Neurooncol 2017;135:433-41.

3. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathol 2012;123:473-84.

4. Gajjar A, Bowers DC, Karajannis MA, Leary S, Witt H, et al. Pediatric brain tumors: innovative genomic information is transforming the diagnostic and clinical landscape. J Clin Oncol 2015;33:2986-98.

5. Gupta T, Shirsat N, Jalali R. Molecular subgrouping of medulloblastoma: impact upon research and clinical practice. Curr Pediatr Rev 2015;11:106-19.

6. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012;123:465-72.

7. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803-20.

8. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29:1408-14.

9. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008;3:e3088.

10. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011;29:1424-30.

11. Kunder R, Jalali R, Sridhar E, Moiyadi A, Goel N, et al. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. Neuro Oncol 2013;15:1644-51.

12. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011;29:1400-7.

13. Kaur K, Kakkar A, Kumar A, Mallick S, Julka PK, et al. Integrating molecular subclassification of medulloblastomas into routine clinical practice: a simplified approach. Brain Pathol 2016;26:334-43.

14. Schwalbe EC, Williamson D, Lindsey JC, Hamilton D, Ryan SL, et al. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 2013;125:359-71.

15. Hovestadt V, Remke M, Kool M, Pietsch T, Northcott PA, et al. Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 2013;125:913-6.

16. Koeller KK, Rushing EJ. From the archives of the AFIP: medulloblastoma: a comprehensive review with radiologic-pathologic correlation. Radiographics 2003;23:1613-37.

17. Gupta T, Sarkar C, Rajshekhar V, Chatterjee S, Shirsat N, et al. Indian society of neuro-oncology consensus guidelines for the contemporary management of medulloblastoma. Neurol India 2017;65:315-32.

18. Kuo MD, Jamshidi N. Behind the numbers: decoding molecular phenotypes with radiogenomics--guiding principles and technical considerations. Radiology 2014;270:320-5.

19. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2016;278:563-77.

20. Kickingereder P, Andronesi OC. Radiomics, metabolic, and molecular MRI for brain tumors. Semin Neurol 2018;38:32-40.

21. Teo WY, Shen J, Su JM, Yu A, Wang J, et al. Implications of tumor location on subtypes of medulloblastoma. Pediatr Blood Cancer 2013;60:1408-10.

22. Perreault S, Ramaswamy V, Achrol AS, Chao K, Liu TT, et al. MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol 2014;35:1263-9.

23. Wefers AK, Warmuth-Metz M, Poschl J, von Bueren AO, Monoranu CM, et al. Subgroup-specific localization of human medulloblastoma based on pre-operative MRI. Acta Neuropathol 2014;127:931-3.

24. Lastowska M, Jurkiewicz E, Trubicka J, Daszkiewicz P, Drogosiewicz M, et al. Contrast enhancement pattern predicts poor survival for patients with non-WNT/SHH medulloblastoma tumours. J Neurooncol 2015;123:65-73.

25. Bluml S, Margol AS, Sposto R, Kennedy RJ, Robison NJ, et al. Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. Neuro Oncol 2016;18:126-31.

26. Patay Z, DeSain LA, Hwang SN, Coan A, Li Y, et al. MR imaging characteristics of wingless-type-subgroup pediatric medulloblastoma. AJNR Am J Neuroradiol 2015;36:2386-93.

27. Keil VC, Warmuth-Metz M, Reh C, Enkirch SJ, Reinert C, et al. Imaging biomarkers for adult medulloblastomas: genetic entities may be identified by their MR imaging radiophenotype. AJNR Am J Neuroradiol 2017;38:1892-8.

28. Zhao F, Li C, Zhou Q, Qu P, Wang B, et al. Distinctive localization and MRI features correlate of molecular subgroups in adult medulloblastoma. J Neurooncol 2017;135:353-60.

29. Mata-Mbemba D, Zapotocky M, Laughlin S, Taylor MD, Ramaswamy V, et al. MRI characteristics of primary tumors and metastatic lesions in molecular subgroups of pediatric medulloblastoma: a single-center study. AJNR Am J Neuroradiol 2018;39:949-55.

30. Zapotocky M, Mata-Mbemba D, Sumerauer D, Liby P, Lassaletta A, et al. Differential patterns of metastatic dissemination across medulloblastoma subgroups. J Neurosurg Pediatr 2018;21:145-52.

31. Dasgupta A, Gupta T, Pungavkar S, Shirsat N, Epari S, et al. Nomograms based on pre-operative multi-parametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: results from a radiogenomics study of 111 patients. Neuro Oncol 2018; doi: 10.1093/neuonc/noy093.

32. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010;468:1095-9.

33. Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. Annu Rev Pathol 2008;3:341-65.

34. Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, et al. Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell 2016;29:508-22.

35. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-45.

36. Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol 2016;131:821-31.

37. Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004;5:399-408.

38. Fossati P, Ricardi U, Orecchia R. Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy. Cancer Treat Rev 2009;35:79-96.

39. Moxon-Emre I, Taylor MD, Bouffet E, Hardy K, Campen CJ, et al. Intellectual outcome in molecular subgroups of medulloblastoma. J Clin Oncol 2016;34:4161-70.

40. Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol 2016;17:484-95.

41. Colafati GS, Voicu IP, Carducci C, Miele E, Carai A, et al. MRI features as a helpful tool to predict the molecular subgroups of medulloblastoma: state of the art. Ther Adv Neurol Disord 2018;11:1756286418775375.

42. Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 2017;31:737-54.

43. Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol 2017;18:958-71.

44. Parmar C, Grossmann P, Bussink J, Lambin P, Aerts HJ. Machine learning methods for quantitative radiomic biomarkers. Sci Rep 2015;5:13087.

45. Zhou M, Scott J, Chaudhury B, Hall L, Goldgof D, et al. Radiomics in brain tumor: image assessment, quantitative feature descriptors, and machine-learning approaches. AJNR Am J Neuroradiol 2018;39:208-16.

Journal of Translational Genetics and Genomics
ISSN 2578-5281 (Online)
Follow Us

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/